Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 27Advanced Solid Tumor 26Solid Tumor 13Solid Tumors 6Advanced Solid Tumour 5Advanced Malignant Solid Tumor 4Metastatic Solid Tumors 2Mesothelioma 2Advanced or Metastatic Solid Tumors 2mCRPC (Metastatic Castration-resistant Prostate Cancer) 1Uveal Melanoma 1Solid Tumor, Adult 1Pediatric Solid Tumor, Unspecified, Protocol Specific 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Malignant Solid Tumors 1Malignant Solid Tumor 1Locally Advanced/Metastatic Solid Tumours 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Solid Tumor 1HER2-Positive Solid Tumors 1Docetaxel 1Colorectal Neoplasms 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumours 1Advanced Solid Tumors Cancer 1Advanced Solid Tumors - Phase 1 Population 1Advanced Solid Tumor (Phase 1) 1Advanced Malignant Solid Tumours 1

Interventions

atezolizumab 1Nivolumab 1NVP-BKM120 1Injections 1E7046 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Solid Tumor × Injections × Other solid neoplasm × Clear all
NCT04975958 2025-06-22

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Completed
47 enrolled
Other solid neoplasm

Locally Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡